Impact of the European clinical trials directive on prospective academic clinical trials associated with BMT.
The European Clinical Trials Directive (EU 2001; 2001/20/EC) was introduced to improve the efficiency of commercial and academic clinical trials. Concerns have been raised by interested organizations and institutions regarding the potential for negative impact of the Directive on non-commercial European clinical research. Interested researchers within the European Group for Blood and Marrow Transplantation (EBMT) were surveyed to determine whether researcher experiences confirmed this view. Following a pilot study, an internet-based questionnaire was distributed to individuals in key research positions in the European haemopoietic SCT community. Seventy-one usable questionnaires were returned from participants in different EU member states. The results indicate that the perceived impact of the European Clinical Trials Directive has been negative, at least in the research areas of interest to the EBMT.
MCB Group, Wageningen University, Wageningen, The Netherlands. Lynn.Frewer@wur.nl
L J
LJ
Frewer
D
D
Coles
I A
IA
van der Lans
D
D
Schroeder
K
K
Champion
J F
JF
Apperley
D035843:Biomedical Research / Q000458:organization & administration; D016026:Bone Marrow Transplantation / Q000592:standards*; D002986:Clinical Trials as Topic; D005060:Europe; D006801:Humans; D011446:Prospective Studies; D011795:Surveys and Questionnaires